Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PALISADE BIO INC
PALI | US
1.89
USD-0.10
-5.03%
PALI | US
About PALISADE BIO INC
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
20/03/2026
Close
1.89
Open
1.98
High
2.02
Low
1.85
Palisade Bio Inc. a clinical-stage biopharmaceutical company focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148 an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions postoperative ileus and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co. Ltd. Palisade Bio Inc. is based in Carlsbad California.
View LessPALI | US
Risk
76.8
Sharpe
1.05
Luna's Score
48/100
Recommendation
Hold
Luna says (PALI | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
71.9%1 month
76.8%3 months
99.3%6 months
139.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.50
Debt to equity
0.05
Debt to assets
0.04
Ent. to EBITDA
0.57
Ent. to rev.
234.89
PEG
-
Other Fundamentals
EBITDA
-14.59M
MarketCap
2.62M
MarketCap(USD)
2.62M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-110.09
Short ratio
1.00
Short perc.
2.04
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.48
Range1M
0.53
Range3M
1.19
Volumes: Market Activity
Rel. volume
0.87
Price X volume
5.38M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.57 | - | Par |
| Ent. to Revenue | 234.89 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.50 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 99.26 | - | Riskier |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 2.62M | - | Emerging |
